Quanterix Corp (QTRX): M&A transaction — Quanterix completes Akoya acquisition for ~7.8M shares + $20M cash; TAM expands to $5B

Quanterix Corp

Quanterix issued ~7.8M shares and paid ~$20M cash to buy Akoya, creating integrated blood & tissue biomarker platform.
Combined addressable market grows from $1B to $5B; company expects accelerated path to profitability by 2026.
CEO Masoud Toloue and CFO Vandana Sriram continue; new board members Scott Mendel and Myla Lai-Goldman appointed.
Prior directors Martin Madaus and Sarah Hlavinka resigned effective at closing; cash balance ~$163M post-transaction.
Historical financials of Akoya and pro forma financials to be filed within 71 days via 8-K/A.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Quanterix Corp completed an acquisition involving Akoya Biosciences, Inc. for approximately 7.8 million shares of its common stock and paid approximately $20 million in cash (closed 2025-07-08).

Action: acquisition
Counterparty: Akoya Biosciences, Inc.
Consideration: approximately 7.8 million shares of its common stock and paid approximately $20 million in cash
Closing: 2025-07-08

Exact text from the filing

Effective Time and (ii) the aggregate Per Share Cash Consideration paid by the Company in connection with the transactions contemplated in the Merger Agreement does not exceed $20,000,000. The foregoing summary of the Merger Agreement and the Merger is not complete and is qualified in its entirety by reference to the complete text of the Merger Agreement, which is

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001503274-25-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.